

Alessandro Peri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/678064/publications.pdf>

Version: 2024-02-01

41
papers

1,352
citations

430754

18
h-index

345118

36
g-index

57
all docs

57
docs citations

57
times ranked

1396
citing authors

#	ARTICLE	IF	CITATIONS
1	Moderate Hyponatremia Is Associated with Increased Risk of Mortality: Evidence from a Meta-Analysis. PLoS ONE, 2013, 8, e80451.	1.1	221
2	Current treatment practice and outcomes. Report of the hyponatremia registry. Kidney International, 2015, 88, 167-177.	2.6	149
3	Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together?. Journal of Endocrinological Investigation, 2020, 43, 1137-1139.	1.8	108
4	Hyponatremia Improvement Is Associated with a Reduced Risk of Mortality: Evidence from a Meta-Analysis. PLoS ONE, 2015, 10, e0124105.	1.1	98
5	The Use of Vaptans in Clinical Endocrinology. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1321-1332.	1.8	75
6	The Economic Burden of Hyponatremia: Systematic Review and Meta-Analysis. American Journal of Medicine, 2016, 129, 823-835.e4.	0.6	75
7	Effects of Hyponatremia on the Brain. Journal of Clinical Medicine, 2014, 3, 1163-1177.	1.0	72
8	Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Journal of Endocrinological Investigation, 2010, 33, 671-682.	1.8	47
9	Hyponatremia, falls and bone fractures: A systematic review and meta-analysis. Clinical Endocrinology, 2018, 89, 505-513.	1.2	37
10	A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans. Clinical Endocrinology, 2017, 86, 761-771.	1.2	36
11	Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. Journal of Endocrinological Investigation, 2020, 43, 337-345.	1.8	33
12	Membrane cholesterol as a mediator of the neuroprotective effects of estrogens. Neuroscience, 2011, 191, 107-117.	1.1	28
13	Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM). Journal of Endocrinological Investigation, 2018, 41, 3-19.	1.8	28
14	A case of osmotic demyelination syndrome occurred after the correction of severe hyponatraemia in hyperemesis gravidarum. BMC Endocrine Disorders, 2014, 14, 34.	0.9	26
15	Low Extracellular Sodium Causes Neuronal Distress Independently of Reduced Osmolality in an Experimental Model of Chronic Hyponatremia. NeuroMolecular Medicine, 2013, 15, 493-503.	1.8	25
16	Management of hyponatremia: causes, clinical aspects, differential diagnosis and treatment. Expert Review of Endocrinology and Metabolism, 2019, 14, 13-21.	1.2	24
17	Low extracellular sodium promotes adipogenic commitment of human mesenchymal stromal cells: a novel mechanism for chronic hyponatremia-induced bone loss. Endocrine, 2016, 52, 73-85.	1.1	22
18	Uteroglobin reverts the transformed phenotype in the endometrial adenocarcinoma cell line HEC-1A by disrupting the metabolic pathways generating platelet-activating factor. International Journal of Cancer, 2000, 88, 525-534.	2.3	19

#	ARTICLE	IF	CITATIONS
19	Neuroprotective effects of estrogens: the role of cholesterol. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 11-18.	1.8	19
20	SIADH: differential diagnosis and clinical management. <i>Endocrine</i> , 2017, 55, 311-319.	1.1	19
21	Practical issues for the management of hyponatremia in oncology. <i>Endocrine</i> , 2018, 61, 158-164.	1.1	19
22	Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. <i>Endocrine</i> , 2021, 74, 172-179.	1.1	19
23	Estrogen receptor-mediated neuroprotection: The role of the Alzheimer's disease-related gene seladin-1. <i>Neuropsychiatric Disease and Treatment</i> , 2008, 4, 817.	1.0	15
24	Management of euvolemic hyponatremia attributed to SIADH in the hospital setting. <i>Minerva Endocrinologica</i> , 2014, 39, 33-41.	1.7	14
25	Hyponatremia and pituitary adenoma: Think twice about the etiopathogenesis. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 750-753.	1.8	12
26	Seladin-1 as a target of estrogen receptor activation in the brain: A new gene for a rather old story?. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 285-293.	1.8	11
27	3 Considerations regarding the management of hyponatraemia secondary to SIADH. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012, 26, S16-S26.	2.2	11
28	Hypothyroidism and hyponatremia: data from a series of patients with iatrogenic acute hypothyroidism undergoing radioactive iodine therapy after total thyroidectomy for thyroid cancer. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 49-54.	1.8	11
29	Effects of low extracellular sodium on proliferation and invasive activity of cancer cells in vitro. <i>Endocrine</i> , 2020, 67, 473-484.	1.1	11
30	Low sodium and tolvaptan have opposite effects in human small cell lung cancer cells. <i>Molecular and Cellular Endocrinology</i> , 2021, 537, 111419.	1.6	10
31	Hyponatraemia alters the biophysical properties of neuronal cells independently of osmolarity: a study on Ni ²⁺ -sensitive current involvement. <i>Experimental Physiology</i> , 2016, 101, 1086-1100.	0.9	9
32	The effects of Exendin-4 on bone marrow-derived mesenchymal cells. <i>Endocrine</i> , 2018, 60, 423-434.	1.1	9
33	A case of malignant insulinoma responsive to somatostatin analogs treatment. <i>BMC Endocrine Disorders</i> , 2018, 18, 98.	0.9	8
34	PPAR β in Neuroblastoma. <i>PPAR Research</i> , 2008, 2008, 1-7.	1.1	6
35	Altered expression of 3-beta-hydroxysterol delta-24-reductase/selective Alzheimer's disease indicator-1 gene in Huntington's disease models. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 729-737.	1.8	6
36	Neuronal distress induced by low extracellular sodium in vitro is partially reverted by the return to normal sodium. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 177-184.	1.8	5

#	ARTICLE	IF	CITATIONS
37	Hyponatremia and Oxidative Stress. <i>Antioxidants</i> , 2021, 10, 1768.	2.2	5
38	Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders. <i>Oncologist</i> , 2020, 25, e946-e954.	1.9	3
39	Tolvaptan efficacy and drug-drug interactions. <i>Minerva Endocrinologica</i> , 2020, 45, 264-265.	1.7	2
40	The V2 receptor antagonist tolvaptan counteracts proliferation and invasivity in human cancer cells. <i>Journal of Endocrinological Investigation</i> , 0, , .	1.8	1
41	Hormonal modulation of cholesterol: experimental evidence and possible translational impact. <i>Expert Review of Endocrinology and Metabolism</i> , 2012, 7, 309-318.	1.2	0